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Abstract
Background: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic ﬁbrosis (CF).
Methods: Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF patients across four time periods
(6–12 (P2) and 0–6 months (P1) pre-initiation, and 0–6 (T1) and 6–12 months (T2) post-initiation). Outcomes were: changes in %-predicted forced
expiratory volume in 1 s (FEV1), body-mass index (BMI), hospitalisation days and intravenous antibiotic usage.
Results:Median FEV1% predicted for each 6-month period was 38.9%, 34.6%, 37.1% and 36.5%; median change was −2.0% between P2 and P1,
increasing to +0.6% (p b 0.001) between P1 and T1. Annualised hospital bed-days was reduced (p = 0.05) post-initiation, as was intravenous
antibiotics days (p = 0.001). BMI increased over 6 months post-initiation (p ≤ 0.001).
Conclusions: In patients with CF in routine practice, inhaled aztreonam lysine is associated with improved lung function and weight, and reduced
hospitalisation and intravenous antibiotic use.
© 2017 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Aztreonam; Cystic ﬁbrosis; Forced expiratory volume; Evaluation tool; Intravenous antibiotics
Abbreviations: BMI, body mass index; CF, cystic fibrosis; FEV1, forced expiratory volume in 1 s; IV, intravenous.
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1. Introduction
Patients with CF are highly susceptible to recurrent, and
ultimately chronic, respiratory tract infections, principally with
Pseudomonas aeruginosa (Pa), which result in progressive
inflammation and irreversible airway damage [1,2]. This chronic
infection leads to recurrent symptomatic exacerbations, which
increase the rate of decline in lung function and are associated with
increased risk of death andmorbidity [3–8]. Inhaled antibiotics are
an established therapeutic option for these patients although
adherence and real-world effectiveness has been less than optimal
in some studies [1,9,10].
Inhaled aztreonam lysine is a recent treatment option with a
rapid delivery system shown in randomised controlled trials to
improve forced expiratory volume in 1 s (FEV1) and reduce
pulmonary exacerbations, compared with placebo in patients
with CF [11,12]. The long-term safety and efficacy of inhaled
aztreonam has been demonstrated [13]. In addition, the efficacy
of inhaled aztreonam was demonstrated in an open-label active
comparator study relative to the perceived current standard of
care, nebulised tobramycin [14]. On the basis of these findings,
inhaled aztreonam lysine is recommended for the treatment of
chronic Pa lung infections in current CF management guidelines
[1,9].
Although randomised controlled trials constitute the ‘gold
standard’ evidence of treatment efficacy, they describe the efficacy
of an intervention only under optimal conditions. They provide
little information about the effectiveness of the treatment under
real-world conditions, for example in patients with advanced
pulmonary disease [15–17]. Adherence to treatment in CF clinical
trials is not typical of that seen in routine practice [10] and trials
have limited ability to demonstrate real cost-effectiveness or the
value within a local health economy. As a consequence of
narrowly defined selection criteria, patients enrolled in respiratory
randomised trials represent fewer than 6% of patients encountered
in routine practice [16,18].
Furthermore, there are a number of limitations associated
with inhaled antibiotic therapy trials. The short duration and on/
off courses of treatment may not be representative of regimens
routinely used in the clinic. Equally there is a lack of evidence
relating to the real-world effectiveness of any specific inhaled
antibiotic in the context of combinations of inhaled antibiotics
typically used in practice. Consequently, real-world studies of
patients with CF are required to provide information that
complements current clinical trial data.
To facilitate assessment of treatment impact on key outcome
measures in patients with CF routinely managed in clinical
practice, we developed a treatment evaluator tool to investigate
the real-world effectiveness of inhaled aztreonam lysine.
2. Materials and methods
2.1. Development of the treatment evaluator tool
The project was conducted over 24 months from January 2012
to January 2014. The treatment evaluator tool was developed
through consensus by an independent Steering Committee with
representatives from nine large cystic fibrosis centres (N100
patients attending service) in Ireland and the UK. Initial meetings
of the Steering Committee were held between January 2012 and
December 2012 to agree and define patient- and treatment-related
information that could be easily recorded during routine clinical
care and would inform real-world treatment outcomes [Table 1].
Genotype classification was determined according to previous
methods [19].
An online, user-friendly interface was developed to facilitate
entry of the agreed data. The treatment evaluator tool assigned a
unique study identity number so as to anonymise the data. Only
the Site Investigator was aware of the actual patient identity.
FEV1% predicted was calculated from absolute measurements
[20].
2.2. Patient selection
The decision to initiate inhaled aztreonam lysine, and/or
discontinue another inhaled antibiotic, was taken by the
specialist CF physician responsible for individual patient care,
based on a clinical need for therapy. Current clinical guidelines
recommend the use of inhaled aztreonam lysine in patients with
chronic Pa lung infections. Patients were seen in routine clinical
practice at one of the nine large adult CF centres participating in
the study. The only entry criteria were attending a participating CF
centre, being 18 years or older at the time of initial data extraction,
and having commenced inhaled aztreonam lysine therapy. The
treatment evaluator tool was completed retrospectively on all
Table 1
Patient- and treatment-related data collected in the treatment evaluator tool.
Baseline patient-related data Treatment-related data On-going patient-related data
Gender
Date of birth
Age
Age at diagnosis of CF
Height
Weight
BMI
Genetic mutations present
Past medical history (including diabetes)
FEV1 (L)
Baseline key nebulised therapy
Treatment changes
IV antibiotic use (at home and in hospital)
Start and stop date of any treatment changes
FEV1 (L)
Height (cm)
Weight (kg)
Exacerbations requiring IV antibiotics
Number of hospital bed days
BMI, body mass index; CF, cystic fibrosis; FEV1, forced expiratory volume in 1 s; IV, intravenous.
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patients at the participating CF centres who commenced inhaled
aztreonam lysine during the data abstraction period.
2.3. Evaluation of outcomes
Participating centres collected baseline data into the treatment
evaluator tool at the visit when inhaled aztreonam lysine was
initiated (time 0), with retrospective data for these patients for the
previous 12 months derived from patient medical notes (including
out-patient and in-patient FEV1 values). Monitoring data were
collected into the treatment evaluator tool during follow-up at
6 months post-initiation of inhaled aztreonam lysine and at
12 months, or at last available follow-up if the patient had less
than 12 months of data at the end of abstraction. The duration of
treatment recorded by the tool was determined by the difference
between inhaled aztreonam lysine start date and the last FEV1
measurement recorded in the treatment evaluator tool. Spirometry
was recorded in keeping with clinical schedules and therefore was
not timed around “on” or “off” months of inhaled therapy. For
analysis, observations were combined into consecutive 6-month
periods, relative to when the patient initiated inhaled aztreonam
lysine therapy: P2 (6–12 months pre-initiation), P1 (0–6 months
pre-initiation), T1 (0–6 months post-initiation) and T2 (6–
12 months post-initiation). For patients with less than 12 months
of follow-up after initiation of inhaled aztreonam lysine therapy,
event rates were annualised to a 12-month event rate to allow
for comparison with the time period pre-initiation of therapy.
Participating centres had access to data from their own patients
and to aggregated data from all centres.
The primary study endpoint was the change in FEV1%
predicted in the 6 months immediately before and after
initiation of inhaled aztreonam lysine therapy (P1 to T1)
relative to the change in the two consecutive 6-month periods
pre-aztreonam (P2 to P1). As each patient had a variable
number of FEV1 assessments, the mean FEV1 for each patient
within each of the 6 month time periods was calculated.
Secondary outcomes were change in hospital bed days per
year, change in IV antibiotics days per year (both total and
categorised by location; home or hospital) and change in body
mass index (BMI) (kg/m2).
2.4. Statistical considerations
As the majority of the study data had a skewed distribution
they are summarised using medians and intra-quartile ranges.
Due to different practice patterns at different sites, the number
of patients with a specific measurement in a given 6-month
period varied; we therefore present data (a) restricting the
analysis to the number of patients with data available at relevant
time periods (b) using all available patient data at each timepoint.
The former approach results in a smaller sample size but ensures
that any differences are not simply the result of different patients
contributing data at different time points. In either case statistical
significance was measured using the Wilcoxon Signed Rank test,
with a type I error rate of ≤0.05. Analysis was conducted using
PASW Statistics version 18.
2.5. Ethical approval and funding
As its purpose is to facilitate a service evaluation of
treatment outcomes as used in current clinical practice, and as
the study involved no direct patient contact and no study-
mandated investigations, the National Research Ethics Service
and appropriate local bodies confirmed that individual ethical
approval was not required for the development of the treatment
evaluator tool and its subsequent use [21]. Funding for tool
development and its use to evaluate outcomes in patients
treated with inhaled aztreonam lysine was provided by Gilead
Sciences UK & Ireland Ltd., which had no access to the data.
Data management was performed by SolverMinds Pharma Ltd.,
Milton Keynes, UK. Data analysis was undertaken by a
researcher who was completely independent of the funder and
of the clinical research group and who had not otherwise been
involved in the data collection. The Steering Committee had
full independent editorial control over the resulting study
manuscript.
3. Results
3.1. Patient characteristics
Data on 117 patients were available for analysis. The median
(interquartile range) duration of follow-up was 37.6 weeks
(22.6–47.9). Table 2 summarises baseline characteristics, which
demonstrate a relatively severe clinical phenotype prior to the
initiation of inhaled aztreonam lysine (median FEV1 36.1%
predicted). The majority of patients were receiving inhaled anti-
pseudomonal treatment prior to initiation of inhaled aztreonam
lysine, with approximately equal proportions treated with colistin
monotherapy (24%), tobramycin monotherapy (20%) or a
combination of the two treatments (24%). The vast majority of
patients were prescribed inhaled aztreonam on an alternate month
basis (19 subjects in conjunction with alternate month nebulised
colistin, 36 with nebulised alternate month tobramycin, 20 with
alternate month inhaled tobramycin); 6 subjects were prescribed
inhaled aztreonam on a continuous basis. A total of 74% had
Table 2
Baseline demographic and treatment characteristics of study population.
Characteristic
Number of patients 117
Males, n (%) 57 (49%)
Age, median years (IQR) 32.0 (25.7, 37.0)
Age at diagnosis b3 years, n (%) 90 (76.9%)
BMI kg/m2, median (range) 21 (9–30)
Diabetes, n (%) 46 (39.3%)
Baseline FEV1% predicted, median (IQR) 36.1 (27.5, 45.3)
Baseline inhaled antibiotic therapy, n (%)
- Colistin monotherapy 27 (24%)
- Tobramycin monotherapy 23 (20%)
- Colistin/tobramycin 27 (24%)
Genotype, n
- Class I–III mutation 87 (74%)
- Class IV–VI mutation 5 (4%)
- Unknown/unclassified 25 (21%)
BMI, body mass index; IQR, interquartile range.
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Class I–III mutations, of which 7 had a Class III mutation. Five
patients had G551Dmutations; two of whom had completed their
one-year follow-up prior to the introduction of ivacaftor. The
remainder could have potentially commenced ivacaftor during
the study follow-up period but this data was not recorded in the
dataset.
3.2. Lung function
One hundred and eight patients had FEV1 data for each of
the three initial 6-month periods, P2, P1 and T1. Lung function
was actively deteriorating in the year prior to therapy, with
the median FEV1% predicted falling significantly from 39.6%
in P2 to 36.2% in P1 (p b 0.001), but it significantly improved
post-initiation of inhaled aztreonam lysine to 38.0% in T1 (p =
0.04), [Table 3]. The median within-patient change in FEV1%
predicted between P2 and P1 was –2.0% (−4.6%, +0.6%) with
77 patients showing a deterioration in their FEV1. The median
within-patient change between periods immediately before (P1)
and immediately after (T1) treatment was +0.6% (−2.0, +3.8)
with only 43 patients manifesting an ongoing deterioration in
their FEV1 following initiation of therapy. The deterioration in
within-patient change in FEV1% predicted was significantly
less following initiation of inhaled aztreonam than prior to its
introduction, (p b 0.001) [Fig. 1A].
Fig. 1B shows FEV1% predicted across the four time periods
using all available measurements. In those patients with available
data, FEV1 deteriorated prior to the initiation of treatment (P2 vs.
P1; p b 0.001) but significantly improved in the 6 months post-
initiation (T1 vs. P1; p = 0.03). The median FEV1 value
remained higher in T2 than P1, but this was non-significant.
Similar trends for the change in FEV1% predicted were evident
when analysis was restricted to the 78 patients who had complete
data in all four periods [Table 3].
Table 3
Distribution of FEV1% predicted by 6-month time period for patients with available data in each of the three initial 6-month periods, in all four 6-month periods and
using all available data.
Time period
6–12 months pre- (P2) 0–6 months pre- (P1) 0–6 months post- (T1) 6–12 months post- (T2)
Complete FEV1% predicted data in each of first three time periods
N 108 108 108 n/a
Median 39.6 36.2 38.0 n/a
p-Value (vs. P1) ⁎ p b 0.001 Reference p = 0.04 n/a
Complete FEV1% predicted data in all four time periods
N 78 78 78 78
Median 38.9 34.6 37.1 36.5
p-Value (vs. P1) ⁎ p b 0.001 Reference p = 0.03 p = 0.48
All available data FEV1% predicted in all four periods
N 110 116 115 83
Median 39.6 36.1 37.3 36.6
p-Value (vs. P1) ⁎ p b 0.001 Reference p = 0.03 p = 0.43
⁎ p values calculated using Wilcoxon Signed Rank test for difference relative to P1 (0–6 months pre-initiation).
Fig. 1. Boxplots showing median within-patient change (solid line), interquartile range (box) and outlying (circle) and extreme outlying (asterisks) values for:
(A) FEV1% predicted between 6 and 12 months (P2) and 0–6 months pre- (P1) initiation of inhaled aztreonam lysine therapy (on left) and between 0 and 6 months
pre- (P1) and 0–6 months post- (T1) initiation of therapy (on right); (B) FEV1% predicted in all patients across the four time periods. p-Values calculated using
Wilcoxon Signed Rank tests.
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3.3. Clinical effectiveness and exacerbation outcomes
The median number of annualised hospital bed-days per
patient decreased by 16% from 15.0 to 12.6 days following
initiation of inhaled aztreonam lysine therapy (p = 0.05)
[Table 4]. The median number of days of intravenous antibiotic
treatment reduced by 26.8% from 56.0 to 41.0 days (p = 0.001)
and significant reductions were seen for both intravenous
antibiotics administered in-hospital, (33% reduction; p = 0.05),
and at home (30% reduction; p = 0.01) [Table 4].
3.4. Body mass index
Median (interquartile range) BMI was stable in the year
prior to initiation of therapy: 20.9 kg/m2 (19.1, 23.1) in P2 and
20.8 kg/m2 (19.1, 23.2) in P1 (p = 0.47). The median BMI
increased significantly to 21.4 kg/m2 (19.4, 23.4) in the 6 months
following initiation of inhaled aztreonam lysine (T1 vs. P1;
p b 0.001), [Fig. 2]. BMI in T2 remained significantly higher
than in P1 at 21.6 kg/m2 (19.2, 23.5) (T2 vs. P1; p = 0.01).
There were similar significant findings when the analysis was
restricted to the 77 patients with complete BMI data at all 4 time
points, median BMI at P2, P1, T1 and T2 of 20.9, 21.0, 21.5 and
21.6 kg/m2 respectively, with T1 being significantly higher than
P1 (p =0.003).
4. Conclusions
This was the first real-world multicentre study of the use of
inhaled aztreonam lysine in clinical practice. Patients evaluated
in the analysis were identified from routine practice at clinics in
the UK and Ireland. The study demonstrates that the ‘real-world’
cohort receiving the therapy had a more severe clinical phenotype
than those documented in clinical trials (a median FEV1 of 36.1%
predicted compared with between 52.2% and 56.7% in clinical
trials) [11–14]. In this real-world population, the introduction
of inhaled aztreonam lysine was associated with significant
improvements in lung function and gain in weight, and a sig-
nificant reduction in hospitalisations and intravenous antibiotic
use, compared to the previous year. These findings are consistent
with the results of the clinical trials conducted for inhaled
aztreonam lysine in selected patient populations [11,12,14].
The patients included in the evaluation were actively deterio-
rating, as shown by the decline in FEV1% predicted and low
BMI prior to therapy, despite the majority of patients receiving
treatment with colistin and/or tobramycin as mono- or dual
therapy. The introduction of inhaled aztreonam lysine in these
patients is consistent with management guidelines [1,9]. The
improved outcomes associated with the introduction of inhaled
aztreonam lysine also raise the question of the potential value if
the therapy had been used earlier, but the current study does not
address this issue.
This study demonstrated a significant reduction in exacerbation
rates which is critical to improving CF outcomes, given that the
number of exacerbations for patients with CF is a significant
predictor of decline in FEV1 [3,5,6] and FEV1 often does not return
to baseline levels after an exacerbation [8]. In our evaluation, we
used hospital bed-days and intravenous antibiotic use as real-world
surrogate measures of exacerbation rate. The observed reduction
in these measures associated with the introduction of inhaled
aztreonam lysine is an important finding with potential benefits for
patients, their families and society; at a fiscal level, these reductions
would result in substantial savings in hospital and community
based costs.
Low body weight in CF is a common problem, and is
associatedwith poor clinical outcomes in CF [22–24]. Addressing
this issue is critical to both acute and chronic care. In our study,
patients showed a median weight gain of 2 kg in the 6 months
following introduction of inhaled aztreonam lysine. Although this
gain is modest, it reversed the decline in weight seen in previous
Table 4
Exacerbation outcomes in the 12 months before and after initiation of inhaled aztreonam lysine. Data are presented as median number of days per patient per year
(interquartile range), using all available data, annualised.
Measure Exacerbation outcomes (median days per patient per year) p-Value
Before inhaled aztreonam lysine After inhaled aztreonam lysine
Hospital bed-days 15.0 (3.5, 45.5) 12.6 (0.0, 43.0) 0.05
Total IV antibiotic days 56.0 (28.0, 93.5) 41.0 (16.5, 73.5) 0.001
In-hospital antibiotic treatment days 19.5 (5.3, 42) 13.0 (0.0, 42.7) 0.05
At-home IV antibiotic treatment days 24.0 (0.0, 55.3) 16.8 (0.0, 41.3) 0.01
IV, intravenous.
Fig. 2. Boxplot showing median (solid line) and interquartile range (box) and
outlying values for body mass index (BMI) across consecutive 6-month periods
using all available data. p-Values calculated using Wilcoxon Signed Rank test.
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months, which may be clinically important in patients with a
severe phenotype awaiting lung transplantation.
In the study reported here, the treatment evaluator tool was
used to evaluate outcomes following the introduction of inhaled
aztreonam lysine but it has potential value in assessing the
impact of a wide range of treatments in the real-world setting.
Although another study on ‘real-world’ effectiveness of inhaled
tobramycin has been reported recently [25], it provided data from
only one centre. The ability to aggregate data from a number of
centres is a useful feature of our tool.
The tool has the potential to provide information about the
clinical effectiveness of a therapy/intervention in a variety of
practice settings, and on the impact of therapy on diverse clinical,
economic and patient-related outcomes. Analysis and comparison
of different mono- and combined inhaled antibiotic therapies in a
‘real-world’ setting is possible, although the current study lacks
sufficient numbers to answer this question. This is of particular
importance given that the recent Aztreonam for Inhalation
Solution Continuous Alternating Therapy (CAT) for Cystic
Fibrosis study failed to achieve its required recruitment due, in
part, to the prevalence of CAT regimens in standard patient care
[26].
This study has some limitations. As an observational study
of routine clinical practice, there was no comparator group, so
conclusions cannot be drawn about the cause of changes seen,
only that there was an association with the treatment initiated.
Data used for comparison before the introduction of the therapy
was obtained retrospectively. Inevitably with a real-world study
using a very mixed patient population, inter-patient variability
may make statistical significance difficult to reach, even for
clinically meaningful changes. As with any observational study,
there is the potential for bias arising from patient selection.
Additionally as measurements were obtained as part of routine
clinical practice across different sites, not all patients had
available measurements at all timepoints. We therefore adopted
two complementary analytical strategies: (1) restricting the
sample to those that had an available measurement from the
period of interest and (2) using all available data points in all
periods. In our analysis both strategies revealed reassuringly
similar findings. Adherence to treatment is a critical aspect of
CF care [10] but the tool and study were not designed to address
this. Finally, the tool was not configured to record the use of
inhaled antibiotics outside of those recommended by the ECFC
guidelines, prior to the initiation of inhaled aztreonam.
The treatment evaluator tool has provided valuable insights
into outcomes in patients with CF in a real-world setting,
demonstrating that the introduction of inhaled aztreonam lysine
was associated with significant improvement in lung function and
gain in weight, and a significant reduction in hospitalisations and
intravenous antibiotic use, compared to the previous year [27].
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